Dexcom has announced that the US Food and Drug Administration (FDA) has approved its G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients aged 2 ...

This morning the Dexcom G6 Pro Continuous Glucose Monitoring System got the greenlight from the FDA. The latest technology can gather real-time glucose data over a period of 10 days and has the ...

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM) announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for ...

DexCom, Inc. DXCM announced that the FDA has approved its G6 Pro Continuous Glucose Monitoring (“CGM”) System for use on patients (aged two years and up). This further fortifies DexCom’s foothold in ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.